Continuous itraconazole treatment for onychomycosis and dermatomycosis: An overview of safety

European Journal of Dermatology

Volumn 9, Issue 7, 1999, Pages 540-543

  Nolting, Siegfried K ^a   Gupta, Aditya ^b   De Doncker, Piet ^c   Jacko, Mary L ^d   Moskovitz, Bruce L ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Continuous therapy; Dermatomycosis; Itraconazole; Onychomycosis; Pulse therapy

Indexed keywords

ITRACONAZOLE; MICONAZOLE;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DERMATOMYCOSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG INTERMITTENT THERAPY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; ONYCHOMYCOSIS; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; SKIN ALLERGY; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

EID: 0032720615     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boonk W, de Geer D, de Kreek E, Remme J, van Huystee B. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses 1999 (in press).
2. Elewski BE, Scher RK, Aly R, Daniel III R, Jones HE, Odom RB, Zaias N, Jacko ML. Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis. Cutis 1997; 59: 217-20.
3. Haneke E, Tajerbashi M, De Doncker P, Heremans A. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconozole. Dermatology 1998; 196: 323-9.
4. Schuller J, Remme JJ, Rampen FHJ, Van Neer FCJ. Itraconazole in the treatment of tinea pedis and tinea manus: comparison of two treatment schedules. Mycoses 1999 (in press).
5. Sugar AM. Fluconazole and itraconazole: current status and prospects for antifungal therapy [review]. Curr Clin Top Infect Dis 1993; 13: 74-98.
6. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions [review]. J Am Acad Dermatol 1993; 29: S50-S4.
7. Karchmer AW, Gibbons GW. Foot infections in diabetes: evaluation and management. Curr Clin Top Infect Dis 1994; 14: 1-22.
8. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, van Peer A, Levron JC, Woestenborghs R, Cauwenbergh G. The pharmacokinetics of itraconazole in animals and man: an overview, In: Recent trends in the discovery, development and evaluation of antifungal agents. Fromtling RA, ed. Barcelona, Spain: JR Prous Science Publishers, 1987: 223-49.
9. Larosa E, Cauwenbergh G, Cilli P, Woestenborghs R, Heykants J. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg of itraconazole. Eur J Obstet Gynecol Reprod Biol 1986; 23: 85-9.
10. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8.
11. Matthieu L, De Doncker P, Cauwenbergh G, Woestenborghs R, van de Velde V, Janssen PAJ, Dockx P. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-6.
12. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J. Van Cutsem J, Cauwenbergh G, Roseeuw D. Post-treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992; 26: 731-5.
13. Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189: 378-81.
14. Gupta AK, De Doncker P, Heremans A, Stoffels P, Piérard GE, Decroix J, Heenen M, Degreef H. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol 1997; 36: 789-92.
15. Roseeuw D, De Doncker P. New therapeutic concepts for the treatment of onychomycosis. J Eur Acad Dermatol Venereol 1993; 2 (suppl. 1): 34-8.
16. Havu V, Brandt H, Heikkila H, Hollmen A, Oksman R, Rantanen T, Saari S, Stubb S, Turjanmaa K, Piepponen T. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-4.
17. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails: a US analysis. Pharmacoeconomics 1998; 13: 243-56.
18. De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Roseeuw D. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132: 34-41.
19. De Doncker P, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycosis: an overview. J Am Acad Dermatol 1997; 37: 969-74.
20. Gupta AK, De Doncker P, Scher RK, Haneke E, Daniel III CR, André J, Baran R. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-8.